Latanoprostene bunod

Drug Profile

Latanoprostene bunod

Alternative Names: BOL-303259-X; NCX-116; PF-03187207; PF-3187207; Vesneo; Vyzulta

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NicOx
  • Developer Bausch & Lomb
  • Class Antiglaucomas; Nitro compounds; Prostaglandins; Small molecules
  • Mechanism of Action Nitric oxide donors; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Glaucoma; Ocular hypertension

Most Recent Events

  • 18 Aug 2017 NicOx reports submitting a response to the complete response letter received from the FDA for latanoprostene bunod in Glaucoma and Ocular hypertension
  • 08 Aug 2017 Valeant Pharmaceuticals receives complete response letter from the FDA for latanoprostene bunod (0.024%) in patients with Glaucoma or Ocular hypertension
  • 22 Mar 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Glaucoma in USA (Ophthalmic) is 2017-08-24
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top